The short answer

No — Wegovy is not FDA-approved for obstructive sleep apnea, so Medicare will not cover Wegovy for sleep apnea. This is the single biggest point of confusion, so it is worth stating plainly: the GLP-1 medication that is FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) is Zepbound (tirzepatide), not Wegovy (semaglutide).

There are two separate things people mix up here, so let us untangle them:

  • The $50 Medicare GLP-1 Bridge is a weight-management program. It does not list sleep apnea as a qualifying condition — so you cannot use the Bridge to get any drug covered for OSA.
  • Zepbound has its own FDA approval for OSA. Because that is a medical indication separate from weight loss, a Medicare Part D plan is allowed to cover Zepbound for sleep apnea — but only if your specific plan lists it.

So if your real goal is treating sleep apnea with a GLP-1, the conversation is about Zepbound, not Wegovy. Here is the full picture.

What the FDA actually approved

In December 2024, the FDA approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA trial, which showed tirzepatide meaningfully reduced sleep apnea severity (measured by the apnea-hypopnea index, or AHI).

Wegovy (semaglutide) does not have an FDA approval for OSA. Losing weight on Wegovy can improve sleep apnea — weight loss of 10–15% often reduces OSA severity — but that is a downstream benefit of weight loss, not an FDA-approved sleep-apnea indication. That distinction matters for coverage, because Medicare coverage follows a drug's approved indications.

Why the $50 Bridge does not cover sleep apnea

The Medicare GLP-1 Bridge is built around weight management, and it covers three drugs — Wegovy, the Zepbound KwikPen, and Foundayo — at a flat $50 a month for people who meet one of three BMI-and-health categories:

  • BMI 35 or higher, or
  • BMI 30 or higher with heart failure, uncontrolled high blood pressure, or chronic kidney disease, or
  • BMI 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease

Sleep apnea is not on any of those lists. Neither is type 2 diabetes or high cholesterol. So the Bridge will not cover any GLP-1 for the purpose of treating OSA. See do you qualify for the $50 Bridge? for the full eligibility rules.

The realistic paths if you have sleep apnea

Path 1 — Qualify for the Bridge on weight grounds

Many people with OSA also live with obesity and one of the Bridge-qualifying conditions above. If you do, your doctor can submit a Bridge prior authorization based on weight management (not OSA), and you would pay $50 a month for Wegovy, the Zepbound KwikPen, or Foundayo. Better-controlled weight often improves sleep apnea as a secondary benefit — but OSA is not the basis for the coverage. Check with our 2-minute eligibility quiz.

Path 2 — Zepbound for OSA through regular Part D

Because Zepbound carries an FDA sleep-apnea indication, a Medicare Part D plan is permitted to cover it for OSA — this is separate from the weight-loss exclusion and separate from the Bridge. The catch: coverage is not automatic. Your specific plan must list Zepbound on its formulary for the OSA indication, and most will require prior authorization with documentation such as a sleep study and AHI results. Not all plans have added it. Call your plan and ask directly:

"Does my Part D plan cover Zepbound (tirzepatide) for obstructive sleep apnea, and what prior authorization do you require?"

This pathway applies to Zepbound, not Wegovy — because Wegovy has no OSA indication for a plan to cover against.

Path 3 — CPAP and standard OSA care

CPAP remains the gold-standard treatment for moderate-to-severe OSA and is well covered under Medicare Part B as durable medical equipment. A GLP-1 like Zepbound may be used alongside CPAP, not necessarily instead of it. Talk to your sleep specialist about whether a medication makes sense in addition to your current treatment.

Questions to ask your doctor and plan

  1. "Do I qualify for the $50 GLP-1 Bridge based on my BMI and health conditions — separate from my sleep apnea?"
  2. "Does my specific Part D plan cover Zepbound for obstructive sleep apnea, and what documentation is needed?"
  3. "What is my AHI and BMI — do I meet the FDA criteria for Zepbound for OSA?"
  4. "Should I consider Zepbound alongside CPAP, or is CPAP alone right for me?"

Data note

Data as of June 2026. Wegovy (semaglutide) does not have an FDA obstructive-sleep-apnea indication; Zepbound (tirzepatide) received that approval in December 2024. The Medicare GLP-1 Bridge covers weight management only and does not list sleep apnea as a qualifying condition. Part D coverage of Zepbound for OSA is plan-specific. Always confirm current details with your plan or Medicare.gov, and talk to your doctor.

For the related coverage picture, see Does Medicare cover Zepbound in 2026? and Does Medicare cover Wegovy in 2026?.